$6.97 -0.01 (%) Amicus Therapeutics Inc - NASDAQ

Nov. 21, 2014 | 04:00 PM

Partner Headlines

  1. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 19, 2014 | 08:18AM EST
  2. Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, Celldex Therapeutics, Amicus Therapeutics, Inter Parfums

    Benzinga | Nov. 18, 2014 | 12:58PM EST
  3. Mid-Afternoon Market Update: Tyson Rises After Q4 Results; DreamWorks Shares Decline

    Benzinga | Nov. 17, 2014 | 14:51PM EST
  4. Mid-Day Market Update: Allergan Jumps On Actavis Bid; Denbury Resources Shares Slip

    Benzinga | Nov. 17, 2014 | 13:23PM EST
  5. Midday Gainers From November 17: Celldex Therapeutics, Amicus Therapeutics, Baker Hughes, Allergan

    Benzinga | Nov. 17, 2014 | 12:34PM EST
  6. Mid-Morning Market Update: Markets Edge Lower; Halliburton To Acquire Baker Hughes For $34.6 Billion

    Benzinga | Nov. 17, 2014 | 10:42AM EST
  7. Morning Market Movers

    Benzinga | Nov. 17, 2014 | 09:51AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 17, 2014 | 08:08AM EST
  9. Top 5 Biotech Stocks Over The Past Year

    Benzinga | Oct. 6, 2014 | 14:28PM EST
  10. 3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus

    Benzinga | Sep. 8, 2014 | 14:25PM EST
  11. Top 5 Performing Biotech Stocks Of 2014

    Benzinga | Sep. 3, 2014 | 12:08PM EST
  12. Morning Market Movers

    Benzinga | Aug. 29, 2014 | 09:41AM EST
  13. The Biotech Stock With The Best One-Week Performance

    Benzinga | Aug. 25, 2014 | 15:46PM EST
  14. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 20, 2014 | 10:15AM EST
  15. Morning Market Movers

    Benzinga | Aug. 20, 2014 | 09:49AM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 20, 2014 | 08:10AM EST
  17. Morning Market Movers

    Benzinga | Jul. 1, 2014 | 09:35AM EST
  18. Amicus Extending Rally On Upgrades

    Benzinga | Jul. 1, 2014 | 09:25AM EST
  19. Benzinga's Top Upgrades

    Benzinga | Jul. 1, 2014 | 08:23AM EST
  20. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 1, 2014 | 08:06AM EST
  21. Morning Market Movers

    Benzinga | Apr. 29, 2014 | 09:43AM EST
  22. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 29, 2014 | 08:09AM EST
  23. Earnings Scheduled For March 3, 2014

    Benzinga | Mar. 3, 2014 | 04:42AM EST
  24. UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of Migalastat Monotherapy

    Benzinga | Nov. 21, 2013 | 07:27AM EST
  25. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga | Nov. 12, 2013 | 16:41PM EST
  26. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

    Benzinga | Oct. 25, 2013 | 15:36PM EST
  27. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga | Sep. 25, 2013 | 12:52PM EST
  28. Amicus, Biogen Announce Deal for Discovery, Development, Commercialization of Parkinson's Treatment

    Benzinga | Sep. 10, 2013 | 07:32AM EST
  29. Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry Monotherapy Study Presented at LDN World Symposium Did Not Meet Primary Endpoint

    Benzinga | Feb. 15, 2013 | 03:32AM EST
  30. Amicus Therapeutics Advances Chaperone-ERT Combo Platform in Pompe Diesease

    Benzinga | Feb. 14, 2013 | 00:36AM EST
  31. Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme Replacement Therapy Co-Administration Study for Pompe Disease

    Benzinga | Jan. 4, 2013 | 00:32AM EST
  32. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 21, 2012 | 03:15AM EST
  33. UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform on Phase III Challenges

    Benzinga | Dec. 21, 2012 | 00:46AM EST
  34. Option Traders Call a Bottom for Amicus Therapeutics

    SchaeffersResearch | Dec. 20, 2012 | 13:50PM EST
  35. GlaxoSmithKline

    IBD | Dec. 19, 2012 | 11:50AM EST
  36. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period Results from First Phase 3 Fabry Monotherapy Study

    Benzinga | Dec. 19, 2012 | 09:06AM EST
  37. Amicus Therapeutics Announces Additional Preliminary Results from Open Label Phase 2 Study

    Benzinga | Nov. 8, 2012 | 14:34PM EST
  38. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus | Nov. 6, 2012 | 04:35AM EST
  39. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 03:16AM EST
  40. UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

    Benzinga | Jul. 18, 2012 | 04:14AM EST
  41. Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume Monday

    FoxBusiness | Jul. 2, 2012 | 06:32AM EST
  42. Benzinga's Top Upgrades with Color for May 8, 2012

    Benzinga | May. 8, 2012 | 06:08AM EST
  43. UPDATE: J.P. Morgan Upgrades Amicus Therapeutics

    Benzinga | May. 8, 2012 | 02:37AM EST
  44. From Earlier: Amicus Therapeutics Prices Underwritten Offering of 10M Shares at $5.70

    Benzinga | Mar. 2, 2012 | 01:30AM EST
  45. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-K)

    GuruFocus | Feb. 28, 2012 | 11:19AM EST
  46. Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease

    Benzinga | Feb. 9, 2012 | 05:41AM EST
  47. Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy Study

    Benzinga | Jan. 6, 2012 | 00:31AM EST
Trading Center